CX-5461
1138549-36-6
99%
2026-07-03
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName CX-5461 Cat No CEI-0326 Description CX-5461 is a potent small-molecule inhibitor of RNA polymerase (Pol) I. CAS No 1138549-36-6 Molecular Weight 513.61 Purity >99% Storage 2 years at -20 centigrade Targets Pol I Molecular Formula C27H27N7O2S Chemical Name 5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo- Solubility DSMO In vitro CX-5461 is a potent small-molecule inhibitor of RNA polymerase (Pol) I. CX-5461 inhibit Pol I in the HCT-116 cells with IC50 of 142 nM. CX-5461 also inhibit Pol I in melanoma A375 cell line and pancreatic carcinoma MIA PaCa-2 cell line with IC50 of 113 nM and 54 nM.CX-5461 directly targets the Pol I machinery and inhibits Pol I transcription at the initiation stage.CX-5461 inhibits Pol I via disruption of the SL1-rDNA complex. And CX-5461 inhibits Pol I transcription without having an effect on DNA replication, protein translation, and general cellular transcription. As RNA polymerase (Pol) I is a multiprotein complex activated widely in cancer cells, CX-5461 can block cancer cell proliferation. CX-5461 inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines. For example,CX-5461 induces autophagy but not apoptosis in A375 and MIA Paca-2 cancer cells. In vivo In two murine xenograft models of human cancers, pancreatic carcinoma (MIA PaCa-2) and melanoma (A375), CX-5461(50 mg/kg) demonstrated significant MIA PaCa-2 TGI with TGI equal to 69% on day 31.By inhibiting Pol I transcription, CX-5461 produce in vivo antitumor responses against solid tumors. category Inhibitors(c1514) cas_num 1138549-36-6 Basic Info-
Product Name:
CX-5461
Other Name:CX-5461;2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-Methylpyrazin-2-yl)Methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxaMide;2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-5H-benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide;CX-5461/CX5461;2-(Hexahydro-4-Methyl-1H-1,4-diazepin-1-yl)-N-[(5-Methyl-2-pyrazinyl)Methyl]-5-oxo-5H-benzothiazolo[3,2-a][1,8]napht;5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-;CX-5461, >=98%;2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3
CAS No.:1138549-36-6
Molecular Formula:C26H28N8O2S
InChIKeys:XGPBJCHFROADCK-UHFFFAOYSA-N
Molecular Weight:516.61792
Exact Mass:513.19469430
UNII:3R4C5YLB9I
DSSTox ID:DTXSID20150591
NCI Thesaurus Code:C126798
Categories:
Characteristics-
PSA:
120
XLogP3:3.3
Density:1.45
Boiling Point:739.9±60.0 °C(Predicted)
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product